SGHT STOCK ANALYSIS

Sight Sciences Inc — price, returns and risk statistics

SGHTSight Sciences Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Devices

Value itDuel

Price summary

Last Close

5.45 $

Jul 2, 26

Market Cap

294 M $

Q1 2026 (TTM)

52-Week Range

3.20 $9.05 $

Return and risk cards

Total Return

%+31.0

Trailing 1-year performance

Volatility

%84.6

Price fluctuation measure

Sharpe Ratio

0.26

Risk/Return ratio

Sortino Ratio

0.31

Downside risk/return

Distance to Peak

%-39.8

Difference from 52-week peak

Maximum Drawdown

-%61.9

Deepest 1-year decline

Seasonality

Seasonality Chart

Year 2023
Year 2024
Year 2025
Current Period 2026
3/3 positive months

Periodic Returns

1M

+25.6%

3M

+54.8%

6M

-31.3%

YTD

-31.3%

1Y

+31.0%

3Y

-36.7%

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date
SGHT-31.3%Gold-3.2%Silver-10.4%S&P 500+9.3%

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The S&P 500 index is measured in its own currency.

Monthly positivity

Monthly Avg Positive/Negative Close

Positive Count
Negative Count
Average Positive %
Average Negative %

Frequently Asked Questions

What is the current Sight Sciences Inc (SGHT) stock price?

SGHT last closed at 5.45 $ (Jul 2, 26). Price data is refreshed after every trading day.

What is the market capitalization of Sight Sciences Inc?

Sight Sciences Inc (SGHT) has a market capitalization of approximately 294 M $ as of the latest reported period.

Who are the main competitors of SGHT?

Key peers of Sight Sciences Inc include Smith & Nephew PLC, Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi, Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi, 4DMEDICAL Ltd, Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S.. A detailed metric comparison is available on the Peers tab.

Go deeper on SGHT

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.